3.0.0 4876 2023-01-11T13:31:49Z 2023-01-11T13:31:49Z House HR 2016-03-23 114 [Congressional Record Volume 162, Number 46 (Wednesday, March 23, 2016)]From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]By Mr. MEEHAN:H.R. 4876.Congress has the power to enact this legislation pursuantto the following:This bill is enacted pursuant to Article I, Section 8,Clause 1 and Article I, Section 8, Clause 18.[Page H1585]]]> hswm00 Ways and Means Committee House Standing hswm02 Health Subcommittee Referred to 2016-03-29T20:20:21Z Referred to 2016-03-23T13:04:40Z hsif00 Energy and Commerce Committee House Standing hsif14 Health Subcommittee Referred to 2016-03-25T14:27:02Z Referred to 2016-03-23T13:04:35Z Comprehensive Addiction and Recovery Act of 2016 114 524 S 2016-07-22 Became Public Law No: 114-198. Related bill CRS Stopping Medication Abuse and Protecting Seniors Act of 2015 114 1913 S 2015-07-30 Read twice and referred to the Committee on Finance. Related bill CRS 2016-03-29 hswm02 Health Subcommittee 1 House committee actions Referred to the Subcommittee on Health. Committee 2016-03-25 hsif14 Health Subcommittee 1 House committee actions Referred to the Subcommittee on Health. Committee 2016-03-23 Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. IntroReferral H11100 2 House floor actions hswm00 Ways and Means Committee 2016-03-23 Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. IntroReferral H11100-A 9 Library of Congress 2016-03-23 Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. IntroReferral H11100 2 House floor actions hsif00 Energy and Commerce Committee 2016-03-23 Introduced in House IntroReferral Intro-H 9 Library of Congress 2016-03-23 Introduced in House IntroReferral 1000 9 Library of Congress M001181 Rep. Meehan, Patrick [R-PA-7] Patrick Meehan R PA 7 N N000015 Rep. Neal, Richard E. [D-MA-1] RICHARD NEAL D MA E. 1 2016-03-23 True R000585 Rep. Reed, Tom [R-NY-23] Tom Reed R NY 23 2016-04-12 False T000462 Rep. Tiberi, Patrick J. [R-OH-12] PATRICK TIBERI R OH J. 12 2016-04-27 False Health Administrative law and regulatory procedures Congressional oversight Consumer affairs Department of Health and Human Services Drug trafficking and controlled substances Drug, alcohol, tobacco use Fraud offenses and financial crimes Government studies and investigations Health care coverage and access Health information and medical records Health technology, devices, supplies Medicare Performance measurement Prescription drugs Health 00 2016-03-23 Introduced in House 2016-04-14T16:00:44Z Medicare Prescription Drug Abuse Prevention Act of 2016

This bill amends title XVIII (Medicare) of the Social Security Act to: (1) authorize a Medicare prescription drug plan (PDP) sponsor to establish a drug management program under which the PDP sponsor may limit an at-risk beneficiary's access to coverage for frequently abused drugs to include only those drugs that are prescribed by selected prescribers and dispensed by selected pharmacies; and (2) require a PDP sponsor to have in place a utilization management tool to prevent drug abuse.

With respect to a drug management program, a PDP sponsor must: (1) provide specified notice to a beneficiary who has been identified by the Centers for Medicare & Medicaid (CMS) as "at-risk" and consequently enrolled in the program; and (2) in selecting prescribers and dispensers, ensure that the beneficiary continues to have reasonable access to drugs. These determinations shall be subject to expedited reconsideration and appeal. A PDP sponsor must review and consider an at-risk beneficiary's preferences regarding prescriber and pharmacy selection.

Certain individuals, including those receiving hospice care or residing in a long-term care facility, are exempted from enrollment in a drug management program.

CMS must, for purposes of quality or performance assessments, review and consider complaints received from at-risk beneficiaries regarding lack of access due to their enrollment in a drug management program. In addition, CMS must establish rules and procedures requiring a PDP sponsor to provide specified program data.

]]> Medicare Prescription Drug Abuse Prevention Act of 2016 Display Title Medicare Prescription Drug Abuse Prevention Act of 2016 Official Title as Introduced To authorize the establishment of programs to prevent prescription drug abuse under the Medicare program, and for other purposes. Introduced in House IH Short Titles as Introduced Medicare Prescription Drug Abuse Prevention Act of 2016 Introduced in House 2016-03-23T04:00:00Z https://www.govinfo.gov/content/pkg/BILLS-114hr4876ih/xml/BILLS-114hr4876ih.xml 2016-03-29 Referred to the Subcommittee on Health. text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. Congressional Research Service, Library of Congress This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.